(Q56909020)
Statements
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization (English)
T F Gajewski
F Fallarino
C Uyttenhove
1 April 1996
scientific article published on 01 April 1996